Key result
Recaticimab lowers LDL-C by ~47 percentage points vs. placebo at 12 weeks.
Why the study?
Many patients with dyslipidemia fail to reach LDL-C goals with statins, and established PCSK9 antibodies require injections every 2-4 weeks. Recaticimab is a humanized anti-PCSK9 monoclonal antibody designed for dosing intervals of up to 12 weeks.
Does recaticimab reduce LDL-C compared with placebo in adults with dyslipidemia?
Meta-Analysis (n=1,657)
Double-blind
Randomized controlled trials
Does recaticimab reduce LDL-C compared with placebo in adults with dyslipidemia?
Recaticimab provides robust ~47% LDL-C reductions across extended dosing intervals of up to 12 weeks in adults with dyslipidemia, offering a less frequent injection alternative to standard PCSK9 monoclonal antibodies.
Supports recaticimab as a less frequent dosing option for LDL-C reduction; extends PCSK9 inhibitor evidence to 12-week intervals.
Low-density lipoprotein cholesterol (LDL-C) is the principal target for preventing atherosclerotic cardiovascular disease, yet many patients do not reach treatment goals with statins, and established proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies require injections every 2-4 weeks. Recaticimab is a humanized anti-PCSK9 monoclonal antibody designed for dosing intervals of up to 12 weeks. We searched PubMed, Scopus, Web of Science, and the Cochrane Library up to March 3, 2026, for randomized controlled trials comparing recaticimab with placebo in adults with dyslipidemia. Four double-blind trials (1657 randomized participants) were included. At week 12, recaticimab reduced LDL-C by 47.31 percentage points relative to placebo (95% confidence interval [CI], -49.87 to -44.75; I2 = 0%), with similar reductions for 150 mg every 4 weeks (-49.63), 300 mg every 8 weeks (-49.43), and 450 mg every 12 weeks (-45.50) (P for subgroup difference = 0.29). Recaticimab also reduced non-high-density lipoprotein cholesterol (-45.17), apolipoprotein B (-42.31), lipoprotein(a) (-31.06), the total cholesterol/high-density lipoprotein cholesterol ratio (-36.94), and the apolipoprotein B/apolipoprotein A1 ratio (-45.28), whereas the change in triglycerides was not significant (-10.05; 95% CI, -20.18 to 0.08).
No takes yet. Share an insight, caveat, or question.
Talkhan et al. (2026) conducted a meta-analysis in Dyslipidemia (n=1,657). Recaticimab vs. Placebo was evaluated on Percentage point reduction in low-density lipoprotein cholesterol (LDL-C) at week 12 relative to placebo (MD -47.31 percentage points, 95% CI -49.87 to -44.75). Recaticimab reduced LDL-C by 47.31 percentage points relative to placebo at week 12 (95% CI -49.87 to -44.75; I2=0%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: